{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Synn CB"],"funding":["National Research Foundation of Korea"],"pagination":["e1364"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8716998"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["<h4>Objectives</h4>AXL-mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti-tumor and anti-metastatic activities of SKI-G-801, a small-molecule inhibitor of AXL, alone and in combination with anti-PD-1 therapy.<h4>Methods</h4><i>In vitro</i> pAXL inhibition by SKI-G-801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti-metastatic potential of SKI-G-801. Furthermore, SKI-G-801, anti-PD-1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.<h4>Results</h4>SKI-G-801 robustly inhibited pAXL expression in various cell lines."],"journal":["Clinical & translational immunology"],"pubmed_title":["SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models."],"pmcid":["PMC8716998"],"funding_grant_id":["2017R1D1A1B0303211014"],"pubmed_authors":["Yun J","Kim CG","Lee S","Lim S","Choi H","Pyo KH","Yun MR","Kim SE","Cho BC","Synn CB","Kim MH","Lee HK","Lee JM","Choi Y","Heo SG","Kim YS","Cho JS","Kim DH","Lim SM","Jo HN","Kim DK","Park S","Ahn BC","Kim HR","Hong MH","Lee EJ","Kim JH","Park CW","Lee SS","Lee YW","Lee W","Yang SD","Byeon Y"],"additional_accession":[]},"is_claimable":false,"name":"SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models.","description":"<h4>Objectives</h4>AXL-mediated activation of aberrant tyrosine kinase drives various oncogenic processes and facilitates an immunosuppressive microenvironment. We evaluated the anti-tumor and anti-metastatic activities of SKI-G-801, a small-molecule inhibitor of AXL, alone and in combination with anti-PD-1 therapy.<h4>Methods</h4><i>In vitro</i> pAXL inhibition by SKI-G-801 was performed in both human and mouse cancer cell lines. Immunocompetent mouse models of tumor were established to measure anti-metastatic potential of SKI-G-801. Furthermore, SKI-G-801, anti-PD-1 or their combination was administered as an adjuvant or neoadjuvant in the 4T1 tumor model to assess their potential for clinical application.<h4>Results</h4>SKI-G-801 robustly inhibited pAXL expression in various cell lines.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-09T11:57:02.114Z","creation":"2022-02-11T15:07:21.754Z"},"accession":"S-EPMC8716998","cross_references":{"pubmed":["35003748"],"doi":["10.1002/cti2.1364"]}}